Confirmatory interleukin-1 receptor antagonist trial in severe sepsis

Objective To determine the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in the treatment of patients with severe sepsis.Design Prospective, randomized, double-blind, placebo-controlled, multicenter trial with a planned, midstudy, interim analysis.